Gundappa Rajaram K, Sud Kamal, Kohli Harbir S, Gupta Krishan L, Joshi Kusum, Sakhuja Vinay
Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Ren Fail. 2002 May;24(3):373-7. doi: 10.1081/jdi-120005372.
Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome. We report a patient with a colonic adenocarcinoma who developed hemolytic uremic syndrome after receiving 85 mg/m2 of the drug. The patient was left untreated and died 5 months after this diagnosis was made, of a second malignancy. Differential diagnosis and treatment of this condition are discussed.
丝裂霉素-C广泛用于恶性肿瘤的治疗，且与包括溶血性尿毒症综合征发生在内的严重剂量相关不良反应有关。我们报告了一名患有结肠腺癌的患者，其在接受85mg/m²该药物治疗后发生了溶血性尿毒症综合征。该患者未接受治疗，在诊断出该疾病5个月后死于第二种恶性肿瘤。本文讨论了这种情况的鉴别诊断和治疗。
